Memantine in dementia: a review of the current evidence
- 9 March 2011
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 12 (5) , 787-800
Abstract
As the world's population ages, the incidence of Alzheimer's disease (AD) is projected to double every 20 years. Understanding the pathogenesis of AD and developing effective treatments is a public health imperative. Memantine is a low- to moderate-affinity, non-competitive NMDA receptor antagonist that is currently approved for the treatment of moderate to severe AD. We discuss the current evidence, emphasizing more recent studies examining the effects of memantine in AD. We also look at the gaps in the current knowledge; the studies that will be required to fill these gaps are also discussed. The present paper reviews: the pharmacology of memantine; evidence for its use in moderate to severe AD, as well as in mild to moderate AD; adverse events related to memantine use; its effects specifically on behaviours including aggression and agitation; the pharmacoeconomics of memantine; and the use of memantine in other dementias. Memantine has shown modest benefits in cognition, function, global and behavioural measures, and has shown little potential for drug-drug interactions. For the treatment of moderate to severe AD, memantine should be offered as a therapeutic option, either on its own, or in combination with a cholinesterase inhibitor.Keywords
This publication has 80 references indexed in Scilit:
- Memantine Improves Cognition and Reduces Alzheimer’s-Like Neuropathology in Transgenic MiceThe American Journal of Pathology, 2010
- Memantine treatment decreases levels of secreted Alzheimer's amyloid precursor protein (APP) and amyloid beta (Aβ) peptide in the human neuroblastoma cellsNeuroscience Letters, 2010
- Spotlight on Memantine in Moderate to Severe Alzheimerʼs Disease†Drugs & Aging, 2010
- Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2009
- Long-term Course and Effectiveness of Combination Therapy in Alzheimer DiseaseAlzheimer Disease & Associated Disorders, 2008
- Visual hallucinations and agitation in Alzheimer's disease due to memantine: report of three casesJournal of Neurology, Neurosurgery & Psychiatry, 2006
- Global prevalence of dementia: a Delphi consensus studyThe Lancet, 2005
- MemantinePharmacoEconomics, 2005
- Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving DonepezilJAMA, 2004
- Resource Utilisation and Cost Analysis of Memantine in Patients with Moderate to Severe Alzheimer??s DiseasePharmacoEconomics, 2003